Page 90 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $9.50
52wk Low $0.37 Helius Medical Technologies HSDT $0.51
642 Newtown Yardley Road
Newtown, PA 18940

(USD - in millions) heliusmedical.com
Market Cap 1.8
Enterprise (1.6)
Basic Shares Out. 3.58 COMPANY OVERVIEW
Float 3.56
Institutional Holdings 3.19% Detailed Analysis:Channelchek.com
Short Interest 0.23
Avg. 90-Day Volume 0.44
Helius Medical Technologies is a leading neurotech company in the
medical device field focused on neurologic deficits using orally applied
technology platform that amplifies the brain’s ability to engage
EPS Data physiologic compensatory mechanisms and promote neuroplasticity,
improving the lives of people dealing with neurologic diseases. The
2022 2023 2024 Company’s first commercial product is the Portable Neuromodulation
CQ1 (57.50) (4.50) (3.08) Stimulator.
CQ2 (48.50) (3.00) (0.64)

CQ3 (6.00) (5.49) (0.99)
CQ4 (8.50) (0.96) (0.88)
CY (52.00) (14.56) (5.66) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.04
ROE (ttm) -259.79
Debt-to-Total Cap. (mrq) 0.60
Fiscal Year End 31-Dec

642 Newtown Newtown PA 18940

Key Executives
CEO: Andreeff, Dane
CFO: Mathiesen, Jeffrey
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures